US FDA Approves Asahi Kasei Herpes Drug Hovilpri

The U.S. Food and Drug Administration has approved Asahi Kasei's oral drug Hovilpri, known generically as pritelivir, for treating refractory herpes simplex virus lesions in immunocompromised adults. The 100 mg tablets represent the first new mechanism of action for such therapies in nearly three decades.

"Today's approval delivers the first FDA-approved treatment for refractory mucocutaneous HSV lesions with a novel mechanism of action in nearly 30 years and marks an important advancement for immunocompromised adults," said Stacy Wheeler, Chief Executive Officer of Asahi Kasei Therapeutics in the U.S. and Europe.

Clinical Trial Efficacy and Mechanism

The regulatory approval was supported by data from a Phase 3 clinical trial evaluating patients with mucocutaneous lesions caused by herpes simplex virus infections that proved resistant to standard treatments, including acyclovir, valacyclovir, or famciclovir. According to the AOL report, Hovilpri achieved complete lesion healing by Day 28 in 63% of patients, compared to 34% for investigator's choice alternative treatments.

Unlike traditional antivirals that target viral DNA polymerase, Hovilpri operates as a helicase-primase inhibitor. This class of medication disrupts the viral enzyme complex responsible for DNA unwinding and replication, offering a distinct pathway for patients whose infections have developed resistance to standard nucleoside analogue therapies.

Corporate Acquisition and Market Rollout

The treatment originated from German drugmaker AiCuris, which Asahi Kasei acquired in April for approximately $919 million to expand its specialty pharmaceutical portfolio. Following the FDA clearance, the company expects Hovilpri to become commercially available in the United States before the end of 2026.

What Refractory Infections Mean for Patients

Immunocompromised individuals, such as transplant recipients or patients undergoing chemotherapy, face severe risks from persistent herpes simplex virus lesions that fail to respond to standard first-line antivirals. The availability of a novel mechanism provides an alternative therapeutic option for managing chronic and treatment-resistant outbreaks in vulnerable populations.